FindTrial
Sign In

Experimental: Tezepelumab

BIOLOGICAL4 trials

Sponsors

AstraZeneca

Conditions

AsthmaChronic Rhinosinusitis With Nasal PolypsHealthy Subjects

Phase 1

Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects
CompletedNCT04362410
AstraZenecaHealthy Subjects
Start: 2020-05-18End: 2020-10-09Updated: 2020-11-17

Phase 3

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
CompletedNCT03347279
AstraZenecaAsthma
Start: 2017-11-23End: 2020-11-12Updated: 2021-11-26
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
CompletedNCT03927157
AstraZenecaAsthma
Start: 2019-06-14End: 2024-08-13Updated: 2025-07-01
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
CompletedNCT04851964
AstraZenecaChronic Rhinosinusitis With Nasal Polyps
Start: 2021-04-22End: 2024-12-11Updated: 2026-01-27

Related Papers

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial
International Forum of Allergy & Rhinology2026-07-29
Use of tezepelumab for chronic rhinosinusitis with nasal polyps by eosinophilic endotype: WAYPOINT post-hoc analysis.
2026-07-20
Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).
2026-01-06
Effect of tezepelumab on asthma exacerbations co-occurring with infection-attributed acute respiratory illnesses.
2025-10-08
Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study.
2025-08-07
Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study
Advances in Therapy2025-05-1910 citations
Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies
Pulmonary Therapy2025-04-26
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
New England Journal of Medicine2025-03-0185 citations
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps.
2024-11-085 citations
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
European Respiratory Journal2024-09-2629 citations
2022 CSACI annual scientific meeting book of abstracts
Allergy Asthma and Clinical Immunology2024-08-06
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
2024-05-279 citations
Population Pharmacokinetic Modeling and Exposure–Efficacy and Body Weight–Response Analyses for Tezepelumab in Patients With Severe, Uncontrolled Asthma
The Journal of Clinical Pharmacology2024-04-174 citations
Patient adherence and response time in electronic patient-reported outcomes: insights from three longitudinal clinical trials.
2024-04-104 citations
Tezepelumab in patients with allergic and eosinophilic asthma
Allergy2023-12-2633 citations
Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase 3b VECTOR Study.
2023-12-082 citations
M21 On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study
2023-11-013 citations
S65 Tezepelumab reduced OCS use in OCS-dependent patients with severe asthma: phase 3b WAYFINDER study interim results
2023-11-012 citations
S119 Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype
2023-11-011 citations
M26 The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study
2023-11-011 citations

49 more papers not shown